Back to homepage

Cardiology and cardiovascular disease

Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial

Authors: José Luis Hernández MD, PhD, Francisco S Lozano MD, PhD, Vincent Riambau MD, PhD, Manuel Almendro-Delia MD, PhD, Juan Cosín-Sales MD, PhD, Sergi Bellmunt-Montoya MD, PhD, Javier Garcia-Alegria MD, PhD, Xavier Garcia-Moll MD, FESC, FACC, Juan José Gomez-Doblas MD, PhD, José R Gonzalez-Juanatey MD, PhD, Carmen Suarez Fernández MD

In this narrative review, data about how to reduce residual risk through the best antithrombotic
approach among patients with peripheral artery disease, with a particular focus
on the COMPASS trial, are updated in order to provide some
practical recommendations about its use in this population.

More▸

Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin

Authors: Lale Tokgözoglu MD, José Luis Zamorano MD

A meeting entitled ‘Current Perspective on the Use of Statins in the Treatment of Dyslipidemic Patients’ was held in Stresa, Italy, on 27–28th June 2019. This meeting report summarizes the main messages of the discussion with a special focus on pitavastatin, whose main features in different settings are described.

More▸

Nail enthesis ultrasound and automated software-guided assessment of bilateral common carotid intima–media thickness in psoriasis and psoriatic arthritis: is there a correlation with clinical and laboratory findings?

Authors: José Alexandre Mendonça PhD, Lucas Nogueira Pansani MD, Mateus Basso Mimoto MD, Igor Tadeu Garcia Ferreira MD, Fernanda Bertucci Sanches MD, Thais de Campos Ferreira Pinto MD, Vania Aparecida Leandro-Merhi PhD, José Luis Braga de Aquino PhD

The objective of this study was to detect and correlate the changes that indicate the inflammatory and atherosclerotic process in psoriasis and psoriatic arthritis patients, using nail ultrasound and carotid artery intima–media thickness radiofrequency software.

More▸

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

Authors: Edgardo Kaplinsky MD

This review describes the results of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial and the recently published Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction (DEFINE-HF) trial. In addition, the thought-to-be mechanisms of action of SGLT2 inhibitors beyond their known glucose-lowering effects.

More▸

Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues

Authors: Ashutosh M Shukla MD, Aparna Wagle Shukla MD

This article reviews the expanding clinical applicability of chloroquine and related drugs includes rheumatological and cardiovascular disorders (CVD), chronic kidney disease (CKD), oncology, and a variety of nonmalarial infections.

More▸